Glenmark Life Sciences Q2 Results FY27: PAT Jumps 51.31% to Rs 196.75 Cr, Revenue Rs 681.99 Cr
- October 29, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Glenmark Life Sciences Q2 Results FY27 were declared on 29 October 2026 on a standalone basis. Revenue rose 15.99% YoY to Rs 681.99 Cr from Rs 587.98 Cr, while net profit grew 51.31% to Rs 196.75 Cr from Rs 130.03 Cr. These quarterly results show positive YoY growth on revenue, Operating Profit and net profit.
Glenmark Life Sciences Ltd (ALIVUS) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The company reported revenue of Rs 681.99 Cr and PAT of Rs 196.75 Cr under the NSE symbol ALIVUS. Glenmark Life Sciences Q2 Results FY27 were released on this results date and are presented as standalone results.
This Glenmark Life Sciences Q2 Results review is a results analysis covering the financial highlights, business drivers, outlook and risks. Univest sets out the declared numbers so the Financial Highlights table below reads alongside what changed in revenue, Operating Profit and net profit. The sections that follow keep to the figures declared on the results date.
Click Here – Get Free Investment Predictions
Glenmark Life Sciences Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 681.99 Cr | Rs 587.98 Cr | +15.99% YoY |
| Operating Profit | Rs 265.19 Cr | Rs 179.17 Cr | +48.01% YoY |
| Net Profit (PAT) | Rs 196.75 Cr | Rs 130.03 Cr | +51.31% YoY |
Source: company filing for Glenmark Life Sciences Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Glenmark Life Sciences Q2 Results: What Stands Out
- Standalone revenue grew 15.99% YoY to Rs 681.99 Cr from Rs 587.98 Cr, a double digit gain in YoY growth for the quarter.
- Operating Profit rose 48.01% YoY to Rs 265.19 Cr from Rs 179.17 Cr in the comparison quarter.
- Net profit increased 51.31% YoY to Rs 196.75 Cr from Rs 130.03 Cr, a faster pace than revenue growth in Glenmark Life Sciences Q2 Results FY27.
- Net profit margin improved to 28.8% from 22.1% in the comparison quarter, while return on equity was 18.41% in FY26.
- The performance analysis comes next and shows how revenue, Operating Profit and net profit moved side by side.
Glenmark Life Sciences Q2 Results FY27: Performance Analysis
Glenmark Life Sciences Q2 Results FY27 show standalone revenue of Rs 681.99 Cr for the July to September 2026 quarter, up 15.99% from Rs 587.98 Cr a year earlier. Operating Profit rose 48.01% to Rs 265.19 Cr and net profit rose 51.31% to Rs 196.75 Cr, so all three lines moved higher YoY.
These quarterly results show profit growing much faster than revenue. Revenue gained 15.99%, Operating Profit gained 48.01% and net profit gained 51.31%. In Glenmark Life Sciences Q2 Results FY27 the three lines therefore moved in the same direction, with profit growth well above revenue growth.
The results analysis also looks at what investors can follow next. The Glenmark Life Sciences Q2 Results can be tracked against later filings for revenue, Operating Profit and net profit. That leads the results analysis to the business factors reported with the quarter. Univest readers can compare each of these lines with the Financial Highlights table above as new filings arrive.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 16.0% year on year to Rs 681.99 Cr in the latest quarter. This growth sits alongside the Operating Profit and net profit moves in the quarterly results.
Net Profit Growth – Net profit rose 51.3% year on year to Rs 196.75 Cr, as reported in Glenmark Life Sciences Q2 Results FY27. That puts net profit growth far ahead of the revenue growth of 16.0% in the same quarter.
Net Profit Margin – Net profit margin improved to 28.8% from 22.1% in the comparison quarter. Return on equity was 18.41% in FY26, which is the full year reference point reported alongside the quarter.
FY27 Outlook After Glenmark Life Sciences Q2 Results
FY27 full year results will depend on the quarters that follow this one. The results analysis shows standalone revenue of Rs 681.99 Cr in Glenmark Life Sciences Q2 Results FY27, and later quarters will show how that level develops against the Rs 587.98 Cr of a year earlier. Full year ratios such as return on equity and return on capital employed will also be reported again with later results.
Net profit and Operating Profit are the lines to follow. The quarter closed with net profit of Rs 196.75 Cr and Operating Profit of Rs 265.19 Cr, and the next filing will show how the YoY comparison moves. Univest Screener users can follow these disclosures, and the watch points lead into the risks.
Key Risks to Watch After Glenmark Life Sciences Q2 Results FY27
Lower Return on Equity
Return on equity declined to 18.41% in FY26 from 18.94% in FY25. In Glenmark Life Sciences Q2 Results FY27 this full year figure sits beside quarterly net profit growth of 51.31%.
Lower Return on Capital
Return on capital employed declined to 24.61% in FY26 from 25.50% in FY25. This is a full year comparison to read alongside the YoY growth reported for the quarter.
Profit Versus Revenue Growth
Net profit grew 51.3% year on year while revenue grew 16.0%, a wide gap between the two lines. This comparison is one to track when the next quarterly figures are declared.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Glenmark Life Sciences Q2 Results FY27 show standalone revenue of Rs 681.99 Cr and net profit of Rs 196.75 Cr for the July to September 2026 quarter. Revenue grew 15.99% YoY and Operating Profit grew 48.01%. Readers following the Glenmark Life Sciences Q2 Results can compare these quarterly results with later standalone results. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Glenmark Life Sciences Q2 Results FY27
What are Glenmark Life Sciences Q2 Results FY27?
Ans. Glenmark Life Sciences Q2 Results FY27 cover the July to September 2026 quarter, with standalone revenue of Rs 681.99 Cr and net profit of Rs 196.75 Cr, as summarised in the Quick Answer at the top.
What is the results date for Glenmark Life Sciences Q2 Results FY27?
Ans. Glenmark Life Sciences Q2 Results FY27 were declared on 29 October 2026, which is the results date for the quarter. This date is stated in the opening paragraphs, which also introduce the standalone basis.
What revenue was reported in Glenmark Life Sciences Q2 Results FY27?
Ans. Glenmark Life Sciences reported revenue of Rs 681.99 Cr in the July to September 2026 quarter, compared with Rs 587.98 Cr a year earlier, as the Financial Highlights table sets out.
What net profit was reported in Glenmark Life Sciences Q2 Results FY27?
Ans. Glenmark Life Sciences reported net profit of Rs 196.75 Cr in the quarter, compared with Rs 130.03 Cr a year earlier, as detailed in the Key Takeaways section.
How much YoY growth did revenue show in Glenmark Life Sciences Q2 Results FY27?
Ans. Revenue in Glenmark Life Sciences Q2 Results FY27 grew 15.99% YoY, so YoY growth was positive, while net profit grew 51.31%, as the Performance Analysis section explains.
Did net profit rise or fall in Glenmark Life Sciences Q2 Results?
Ans. Net profit rose in Glenmark Life Sciences Q2 Results, moving from Rs 130.03 Cr to Rs 196.75 Cr, a 51.31% YoY change, which the Performance Analysis section walks through.
What was the Operating Profit in Glenmark Life Sciences Q2 Results FY27?
Ans. Operating Profit in Glenmark Life Sciences Q2 Results FY27 was Rs 265.19 Cr, up 48.01% YoY from Rs 179.17 Cr, while revenue was Rs 681.99 Cr, as the Financial Highlights table shows.
Are Glenmark Life Sciences Q2 Results consolidated results or standalone results?
Ans. Glenmark Life Sciences Q2 Results are standalone results, so every figure here is on a standalone basis, alongside revenue of Rs 681.99 Cr and net profit of Rs 196.75 Cr in the Financial Highlights.
What business factors shaped Glenmark Life Sciences Q2 Results FY27?
Ans. Business factors in Glenmark Life Sciences Q2 Results FY27 include revenue growth of 16.0%, net profit growth of 51.3% and a net profit margin of 28.8%, as the Key Business Factors section lists.
What are the key risks after Glenmark Life Sciences Q2 Results FY27?
Ans. The key risks after Glenmark Life Sciences Q2 Results FY27 are lower return on equity of 18.41%, lower return on capital employed of 24.61% and the gap between profit and revenue growth, which the Key Risks section covers.
What is the outlook after Glenmark Life Sciences Q2 Results?
Ans. FY27 full year results after Glenmark Life Sciences Q2 Results will depend on subsequent quarters, while standalone revenue of Rs 681.99 Cr is the reference, as the Outlook section describes.
Where can I find the complete Glenmark Life Sciences Q2 Results FY27 data?
Ans. The complete Glenmark Life Sciences Q2 Results FY27 data sits in the Financial Highlights table, while the Univest Screener lets users follow later filings for Glenmark Life Sciences alongside the same standalone figures.
